arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

TELA Bio, Inc.

TELA
$1.29 ▼ -0.13 (-9.12%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
10 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

TELA Bio, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $60.6M
Dividend Yield —
Revenue Growth 15.8% ↘
Op. Margin -42.0% ↗
ROIC -54.8% ↘
FCF / Share $-0.61 ↗
Trailing P/E —
Price / Book 9.1x
FCF Yield —
Debt / Equity 8.82
info Valuation on last close. End-of-day price, Sep 23, 2026.

10-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$80.28M
↑ +15.8% —
Net Income Profit after all expenses
$-38.83M
↓ -2.6% —
Operating Margin Operating profit as % of sales
-42.0%
↑ +14.6% 6th
FCF / Share Free cash flow per share
$-0.61
↑ +59.1% —
Long-Term Debt Long-term obligations
$55.65M
↑ +35.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
6
Financial Health ↑
18
Cash Quality ↓
50

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 36 quarters